2 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Approved WMOCompleted
The main objective of this study is to validate a VR foot pedalling paradigm to study visual cueing and freezing of gait in patients with PD-FOG, to allow for its use in future neuroimaging studies. The secondary objective is to assess the influence…